Segment Information - Schedule of Significant Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Aug. 31, 2026 |
Aug. 31, 2025 |
Aug. 31, 2026 |
Aug. 31, 2025 |
|
| Segment Reporting [Line Items] | ||||
| Total research and development expenses | $ 79,260 | $ 86,120 | $ 251,049 | $ 233,879 |
| Reportable Segment | ||||
| Segment Reporting [Line Items] | ||||
| Total research and development expenses | 79,260 | 86,120 | 251,049 | 233,879 |
| Bexobrutideg (NX-5948) | Reportable Segment | ||||
| Segment Reporting [Line Items] | ||||
| Total research and development expenses | 19,975 | 25,143 | 72,141 | 59,421 |
| Zelebrudomide (NX-2127) | Reportable Segment | ||||
| Segment Reporting [Line Items] | ||||
| Total research and development expenses | 681 | 1,389 | 3,754 | 4,054 |
| NX-1607 | Reportable Segment | ||||
| Segment Reporting [Line Items] | ||||
| Total research and development expenses | 1,473 | 1,492 | 4,399 | 5,784 |
| Internal research and development expenses | Reportable Segment | ||||
| Segment Reporting [Line Items] | ||||
| Total research and development expenses | $ 57,131 | $ 58,096 | $ 170,755 | $ 164,620 |
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|